![M. Boyd](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
M. Boyd
No open positions remaining
Net worth: 76 295 $ as of 31/05/2026
Profile
M.
Cantey Boyd is an Independent Director at Kiniksa Pharmaceuticals International Plc since 2024.
Former positions include Director at Aquinox Pharmaceuticals, Inc., Director and Independent Director at Neoleukin Therapeutics, Inc., and Principal at Baker Bros.
Advisors LP.
Education includes undergraduate studies at Brown University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0% | 06/04/2026 | 1,577 ( 0% ) | 76 295 $ | 31/05/2026 |
M. Boyd active positions
| Companies | Position | Start |
|---|
Former positions of M. Boyd
| Companies | Position | End |
|---|---|---|
| NEUROGENE INC. | Director/Board Member | - |
Neoleukin Therapeutics, Inc. /old/
 Neoleukin Therapeutics, Inc. /old/ Pharmaceuticals: MajorHealth Technology Develops medicines that transform lives | Director/Board Member | - |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in identification and development of therapeutics for inflammatory diseases and cancer | Director/Board Member | - |
Baker Bros. Advisors LP
 Baker Bros. Advisors LP Investment ManagersFinance BBA pursues a fundamentally driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. | Analyst-Equity | - |
Training of M. Boyd
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
4
1st degree connections
5
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Baker Bros. Advisors LP
Baker Bros. Advisors LP Investment ManagersFinance BBA pursues a fundamentally driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. | Finance |
Brown University
 Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in identification and development of therapeutics for inflammatory diseases and cancer | Health Technology |
Neoleukin Therapeutics, Inc. /old/
Neoleukin Therapeutics, Inc. /old/ Pharmaceuticals: MajorHealth Technology Develops medicines that transform lives | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Develops de novo – therapeutic proteins to treat serious immunological disorders, including cancer and autoimmunity | Health Technology |
- Stock Market
- Insiders
- M. Boyd
